Sch 1Fees

Schedule 1 — Fees [r. 5] Division 1 — Fees for licences | **Item** | **Type of licence** | **Application fee $** | **Licence fee $** | | 1. | Indent licence | 167 | 113 | | 2. | Schedule 2 retail licence | 113 | 113 | | 3. | Schedule 7 retail licence | 225 | 167 | | 4. | Schedule 9 licence | 225 | 167 | | 5. | Wholesaler’s/manufacturer’s licence | 340 | 283 | [Division 1 inserted: SL 2025/104 r. 16.] Division 2 — Fees for permits | **Item** | **Type of permit** | **Application fee $** | **Permit fee $** | | 1. | Health service permit | 225 | 167 | | 2. | Health service permit — Department/hospital | nil | nil | | 3. | Health service permit — Public sector agency | 225 | 167 | | 4. | Government permit | 167 | 113 | | 5. | Industrial permit | 197 | 141 | | 6. | Pharmaceutical samples permit | 113 | 113 | | 7. | Research/Education permit | 167 | 113 | | 8. | Schedule 9 permit | 225 | 167 | | 9. | Stockfeed manufacture permit | 113 | 113 | | 10. | Veterinary practice permit | 167 | 113 | [Division 2 inserted: SL 2025/104 r. 16.] Division 3 — Other fees | **Item** | **Provision of Act** | **Description of matter** | **Fee $** | | 1. | s. 48(3)(b) | Application to vary licence or permit | 90 | | 2. | s. 52(2)(b) | Application to vary conditions imposed on licence or permit | 90 | | 3. | s. 55(2)(b) | Application for approval of proposed change of management | 90 | | 4. | s. 57(2)(b) | Application for approval after change of management | 90 | | 5. | s. 67 | Issue of replacement licence or permit | 46 | | 6. | s. 68(1) | Provision of certified copy of licence or permit | 90 | | 7. | s. 76(3) | Provision of copy of all or part of the register | 46 | | 8. | s. 76(3) | Provision of certified copy of all or part of the register | 90 | | 9. | s. 91(3) | Provision of copy of information included on the drugs of addiction record in relation to a person | 90 | | 10. | s. 91(3) | Provision of certified copy of information included on the drugs of addiction record in relation to a person | 136 | [Division 3 inserted: SL 2025/104 r. 16.] Schedule 2 — List of additional substances that are Schedule 9 poisons [r. 6] | N‑(adamantan‑1‑yl)‑1‑(5‑fluoropentyl)‑1H‑indole‑3‑carboxamide (STS‑135) | | --- | | N‑((3s,5s,7s)‑adamantan‑1‑yl)‑1‑(5‑fluoropentyl)‑1H‑indazole‑3‑carboxamide (5‑F AKB48 or 5‑F APINACA) | | N‑(1‑adamantyl)‑1‑pentyl‑1H‑indole‑3‑carboxamide (2NE1 or SDB‑001) | | N‑(1‑adamantyl)‑1‑pentyl‑1H‑indazole‑3‑carboxamide (AKB48 or APINACA) | | ALPHA‑pyrrolidinovalerophenone (Alpha‑PVP) | | N‑[1‑(aminocarbonyl)‑2,2‑dimethylpropyl]‑1‑pentyl‑1H‑indazole‑3‑carboxamide (ADB‑PINACA) | | N‑[1‑(aminocarbonyl)‑2‑methylpropyl]‑1‑(cyclohexylmethyl)‑1H‑indazole‑3‑carboxamide (AB‑CHMINACA) | | N‑[(1S)‑1‑(aminocarbonyl)‑2‑methylpropyl]‑1‑(5‑fluoropentyl)‑1H‑indazole‑3‑carboxamide (5F‑AB‑PINACA) | | N‑[(1S)‑1‑(AMINOCARBONYL)‑2‑METHYLPROPYL]‑1‑(5‑FLUOROPENTYL)‑1H‑PYRROLO[2,3‑B]PYRIDINE‑3‑CARBOXAMIDE (5F‑AB‑P7AICA) | | N‑[(1S)‑1‑(aminocarbonyl)‑2‑methylpropyl]‑1‑[(4‑fluorophenyl)methyl]‑1H‑indazole‑3‑carboxamide (AB‑FUBINACA) | | N‑[(1S)‑1‑(aminocarbonyl)‑2‑methylpropyl]‑1‑pentyl‑1H‑indazole‑3‑carboxamide (AB PINACA) | | 6‑(2‑AMINOPROPYL)benzofuran (6‑APB) | | N‑(1‑amino‑3,3‑dimethyl‑1‑oxobutan‑2‑yl)‑1 ‑(cyclohexylmethyl)‑1H‑indazole‑3‑carboxamide (MAB‑CHMINACA or ADB‑CHMINACA) | | N‑(1‑amino‑3,3‑dimethyl‑1‑oxobutan‑2‑yl)‑1‑(5‑fluoropentyl)‑1H‑indole‑3‑carboxamide (5F‑ADBICA) | | N‑(1‑amino‑3‑methyl‑1‑oxobutan‑2‑yl)‑1‑(5‑fluoropentyl)‑1H‑indole‑3‑carboxamide (5F‑ABICA) | | 1‑BUTYL‑N‑(2‑PHENYLPROPAN‑2‑YL)‑1H‑INDOLE‑3‑CARBOXAMIDE (CUMYL‑BICA) | | [3‑(3‑carbamoylphenyl)phenyl]N‑cyclohexylcarbamate (URB‑597) | | (E)‑4‑chloro‑N‑(1‑(4‑nitrophenethyl)piperidin‑2‑ylidene)benzenesulfonamide (W‑18) | | (1R,2S,3S,5S)‑3‑(4‑chlorophenyl)‑8‑methyl‑2‑[3‑(4‑methylphenyl)‑5‑isoxazolyl]‑8‑azabicyclo[3.2.1]octane (RTI‑336) | | 1‑(4‑CYANOBUTYL)‑N‑(1‑METHYL‑1‑PHENYLETHYL)‑1H‑INDAZOLE‑3‑CARBOXAMIDE (SGT‑78; 4‑CN‑CUMYL‑BINACA; CUMYL‑CB‑PINACA; CUMYL‑CYBINACA; 4‑CYANO CUMYL‑BUTINACA) | | Cyclohexyl‑[1,1‑biphenyl]‑3‑ylcarbamate (URB‑602) | | 1‑CYCLOHEXYL‑4‑(1,2‑DIPHENYLETHYL)PIPERAZINE (MT‑45; IC‑6) | | 1‑(cyclohexylmethyl)‑1H‑indole‑3‑carboxylic acid 8‑quinolinyl ester (BB‑22) | | 1‑CYCLOHEXYLETHYL‑3‑(2‑METHOXYPHENYLACETYL)INDOLE (RCS‑8) | | Desoxypipradrol (2‑DPMP) | | 2,5‑DIHYDRO‑2‑(1‑METHYL‑1‑PHENYLETHYL)‑5‑PENTYL‑1H‑PYRIDO[4,3‑B]INDOL‑1‑ONE (CUMYL‑PEGACLONE; SGT‑151) | | Diphenidine | | 1‑(5‑fluoropentyl)‑1H‑indole‑3‑carboxylic acid 8‑quinolinyl ester (5F‑PB22) | | [1‑(5‑fluoropentyl)‑1H‑indol‑3‑yl]‑(2,2,3,3‑tetramethylcyclopropyl)methanone (XLR11 or 5‑fluoro UR144) | | 1‑(5‑fluoropentyl)‑3‑(4‑methyl‑1‑naphthoyl)indole (MAM‑2201) | | 1‑(5‑fluoropentyl)‑N‑(1‑methyl‑1‑phenylethyl)‑1H‑indazole‑3‑carboxamide (SGT‑25) | | 1‑(5‑FLUOROPENTYL)‑3‑(1‑NAPHTHOYL)INDOLE (AM‑2201) | | 5‑(5‑FLUOROPENTYL)‑2‑(2‑PHENYLPROPAN‑2‑YL)‑2,5‑DIHYDRO‑1H‑PYRIDO[4,3‑B]INDOL‑1‑ONE (5F‑CUMYL‑PEGACLONE; 5F SGT‑151) | | 2‑(2‑FLUOROPHENYL)‑2‑METHYLAMINO‑CYCLOHEXANONE (2‑FLUORODESCHLOROKETAMINE; 2FDCK) | | 1‑HEXYL‑3‑(1‑NAPHTHOYL)INDOLE (JWH‑019) | | 9‑(HYDROXYMETHYL)‑6,6‑DIMETHYL‑3‑(2‑METHYLOCTAN‑2‑YL)‑6A,7,10,10A‑TETRAHYDROBENZO[C]CHROMEN‑1‑OL (HU‑210) | | N‑(2‑methoxylbenzyl)‑2,5‑dimethoxy‑4‑bromophenethylamine (25B‑NBOMe) | | N‑(2‑methoxylbenzyl)‑2,5‑dimethoxy‑4‑chlorophenethylamine (25C‑NBOMe) | | N‑(2‑methoxylbenzyl)‑2,5‑dimethoxy‑4‑iodophenethylamine (25I‑NBOMe) | | 2‑Methoxydiphenidine (2‑MXP or MXP) | | 4‑METHOXYPHENYL(1‑BUTYL‑1H‑INDOL‑3‑YL)‑METHANONE (RCS‑4 (C4)) | | 2‑(4‑METHOXYPHENYL)‑1‑(1‑PENTYL‑1H‑INDOL‑3‑YL)‑ETHANONE (JWH‑201) | | 2‑(3‑METHOXYPHENYL)‑1‑(1‑PENTYLINDOL‑3‑YL)ETHANONE (JWH‑302) | | METHYL 2‑(9‑(CYCLOHEXYLMETHYL)‑9H‑CARBAZOLE‑3‑CARBOXAMIDO)‑3,3‑DIMETHYLBUTANOATE (MDMB‑CHMCZCA) | | METHYL 2‑[1‑(4‑FLUOROBENZYL)‑1H‑INDOLE‑3‑CARBOXAMIDO]‑3‑METHYLBUTANOATE (MMB‑FUBICA; AMB‑FUBICA) | | METHYL 2‑[[1‑(4‑FLUOROBUTYL)INDAZOLE‑3‑CARBONYL]AMINO]‑3,3‑DIMETHYL‑BUTANOATE (4F‑MDMB‑BINACA; 4F‑MDMB‑BUTINACA) | | methyl (S)‑2‑[1‑(5‑fluoropentyl)‑1H‑indazole‑3‑carboxamido]‑3,3‑dimethylbutanoate (5F‑ADB) | | methyl 2‑(1‑(5‑fluoropentyl)‑1H‑indazole‑3‑carboxamido)‑3‑methylbutanoate (5F‑AMB) | | METHYL 2‑[[1‑(5‑FLUOROPENTYL)INDOLE‑3‑CARBONYL]AMINO]‑3,3‑DIMETHYL‑BUTANOATE (5‑FLUORO MDMB‑PICA; 5F‑MDMB‑PICA) | | 5,6‑methylenedioxy‑2aminoindane (MDAI) | | 4‑methylethylcathinone (4‑MEC) | | 1‑[(N‑methylpiperidin‑2‑yl)methyl]‑3‑(1‑adamantoyl)indole (AM‑1248) | | 1‑[(N‑methylpiperidin‑2‑yl)methyl]3‑(2‑iodobenzoyl)indole (AM‑2233) | | 1‑[(N‑methylpiperidin‑2‑yl)methyl]3‑(4‑methyl‑1‑naphthoyl)indole (MAM‑1220) | | 1‑[(N‑methylpiperidin‑2‑yl)methyl]3‑(1‑naphthoyl)indole (AM‑1220) | | N‑METHYL‑1‑(THIOPHEN‑2‑YL)PROPAN‑2‑AMINE (METHIOPROPAMINE; MPA) | | [1‑(2‑morpholin‑4‑ylethyl)‑1H‑indol‑3‑yl]‑(2,2,3,3‑tetramethylcyclopropyl)methanone (A796,260) | | N‑(1‑NAPHTHYL)‑1‑(5‑FLUOROPENTYL)‑1H‑INDOLE‑3‑CARBOXAMIDE (5F‑NNEI; 5F‑MN‑24) | | N‑(1‑naphthyl)‑1‑pentyl‑1H‑indole‑3‑carboxamide (NNEI) | | 1‑pentyl‑3‑(1‑adamantoyl)indole (AB‑001) | | 1‑PENTYL‑3‑(4‑CHLORO‑1‑NAPHTHOYL)INDOLE (JWH‑398) | | 1‑PENTYL‑3‑(2‑CHLOROPHENYLACETYL)INDOLE (JWH‑203) | | 1‑PENTYL‑3‑(4‑ETHYL‑1‑NAPHTHOYL)INDOLE (JWH‑210) | | 1‑pentyl‑1H‑indole‑3‑carboxylic acid 8‑quinolinyl ester (PB22) | | 1‑PENTYL‑3‑[(4‑METHOXY)‑BENZOYL]INDOLE (RCS‑4) | | 1‑pentyl‑3‑(2‑methoxybenzoyl)indole (RCS‑4 (2‑methoxy isomer)) | | 1‑PENTYL‑3‑(4‑METHOXY‑1‑NAPHTHOYL)INDOLE (JWH‑081) | | (1‑pentylindol‑3‑yl)‑(2,2,3,3‑tetramethylcyclopropyl)methanone (UR144) | | PRAVADOLINE (WIN 48098) | | 1‑PROPYL‑2‑METHYL‑3‑(1‑NAPHTHOYL)INDOLE (JWH‑015) | | 2,3,5‑trimethoxyamphetamine (TMA‑4) | [Schedule 2 amended: SL 2020/214 r. 7.]